CytoDyn, Inc. Form 8-K Filing

CytoDyn, Inc. filed a Form 8-K on April 30, 2026, to report on an investor call and webcast held to provide corporate and clinical updates. The company presented information on its drug candidate, leronlimab, highlighting its potential in immuno-oncology, specifically for metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC). For mCRC, the Phase 2 CLOVER study showed promising results with early ctDNA declines and tumor shrinkage in patients treated with leronlimab in combination with other therapies. The company also discussed its clinical plan for CRC, including further studies and a collaboration with City of Hope. For TNBC, preclinical and retrospective clinical data suggest leronlimab may reduce metastasis and upregulate PD-L1, potentially improving outcomes when combined with immune checkpoint inhibitors. CytoDyn outlined its clinical priorities and upcoming milestones for 2026, focusing on confirming leronlimab's efficacy, biomarker development, and seeking regulatory designations.